Mouse Anti-BTN3A1 Recombinant Antibody (clone 20.1)

Customer Review

There are currently no Customer reviews or questions for PABL-414. Click the button above to contact us or submit your feedback about this product.

Michael Roberts
09.Apr,23

Excellent for BTN3A1 Detection

The Anti-BTN3A1 Recombinant Antibody (clone 20-1) has been excellent for our BTN3A1 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Sarah Green
11.Jul,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for BTN3A1 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Laura Young
25.Sep,21

Consistent High-Quality Results

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for BTN3A1 have been particularly beneficial.

Q&As

1. Is the anti-BTN3A1 recombinant antibody clone 20.1 suitable for use in Western blotting?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 20.1 (PABL-414) is suitable for use in Western blotting. It provides specific binding to BTN3A1, allowing for reliable detection in Western blot assays.

2. What are the recommended storage conditions for the anti-BTN3A1 recombinant antibody clone 20.1?

   A: The recommended storage condition for the anti-BTN3A1 recombinant antibody clone 20.1 (PABL-414) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-BTN3A1 recombinant antibody clone 20.1 be used in immunoprecipitation assays?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 20.1 (PABL-414) can be used in immunoprecipitation assays. It provides specific binding to BTN3A1, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-BTN3A1 recombinant antibody clone 20.1 effective in ELISA applications?

   A: Yes, the anti-BTN3A1 recombinant antibody clone 20.1 (PABL-414) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of BTN3A1.

5. What is the optimal dilution for using the anti-BTN3A1 recombinant antibody clone 20.1 in immunofluorescence?

   A: The optimal dilution for using the anti-BTN3A1 recombinant antibody clone 20.1 (PABL-414) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Girard, Pauline, et al. "Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes." Clinical & Translational Immunology 10.11 (2021): e1329. https://doi.org/10.1002/cti2.1329
   This study investigates the dysfunctional BTN3A and its interaction with deregulated immune checkpoints and type I/II interferons in the context of melanoma. The research focuses on the roles of plasmacytoid dendritic cells (pDCs) and gamma-delta (γδ) T cells, examining their phenotypic and functional interactions in both the blood and tumor microenvironment of melanoma patients. The study highlights severe alterations in the bidirectional cross-talk between pDCs and γδ T cells in melanoma, noting that while healthy pDCs can drive potent activation of γδ T cells, those from melanoma patients exhibit impaired functionality.
   Creative Biolabs provided critical reagents for this study, specifically anti-BTN3A agonist antibody (clone 20.1, Cat# PABL-414) and anti-BTN3A blocking antibody (clone 103.2, Cat# PABL-415). These antibodies were used to assess the functionality of BTN3A on γδ T cells and pDCs within PBMCs and tumor infiltrates. The use of these antibodies was essential in revealing the potential functional impairment of BTN3A in melanoma patients, thereby providing insights into the therapeutic targeting of BTN3A to improve immune responses in cancer therapy​.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# PABL-414, RRID: AB_3111654)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "Clone 20.1"

See other products for "BTN3A1"

Select a product category from the dropdown menu below to view related products.